Incidence of spontaneous remission in patients with CD25-Positive mycosis fungoides/Sézary syndrome receiving placebo

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages 867-875

  Prince, H Miles ^a   Duvic, Madeleine ^b   Martin, Ann ^c   Sterry, Wolfram ^d   Assaf, Chalid ^d,e   Straus, David J ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HELIOS KLINIKUM KREFELD   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cutaneous T cell lymphoma; Denileukin diftitox; Lymphoma; Mycosis fungoides; Placebo; Spontaneous remission; S zary syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO;

ARTICLE; HUMAN; INTENTION TO TREAT ANALYSIS; METABOLISM; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; PATHOLOGY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; SEZARY SYNDROME; SKIN TUMOR; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; HUMANS; INTENTION TO TREAT ANALYSIS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; NEOPLASM REGRESSION, SPONTANEOUS; PLACEBOS; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 84870897499     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.12.027     Document Type: Article

References (18)

1. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;45:700-6
2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas v.1.2011. Fort Washington, PA: National Comprehensive Cancer Network 2011. Available from: URL:http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed October 10, 2011.
4. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113: 5064-73
5. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:1870-7
6. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008;159: 105-12
7. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 1997;89:32-40
8. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2002;2:222-8
9. Kim YH, Jensen RA, Watanabe GL, Varghese A, HoppeRT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 1996;132:1309-13
10. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25
11. Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008;8(Suppl):S187-92
12. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28:4730-9
13. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995;131:1003-8
14. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Arch Dermatol 2003;139:857-66
15. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 1999;85:208-12
16. Toro JR, Stoll HL Jr, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997;37:58-67
17. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10
18. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-71.